News and Events
News from our Team
Brenda Weigel, MD, MsC, Brendan Moriarity, PhD, and David Largaespada, PhD highlighted in an article "A new cancer treatment is in clinical trial thanks to Zach Sobiech fund", which was featured in the Pioneer Press and the Bemidji Pioneer on February 12, 2018.
Beginning in December 2017, David Largaespada will become the Director of the Center for Genome Engineering (CGE).
Kurata M, Yamamoto K, Moriarity BS, Kitagawa M, Largaespada DA. "CRISPR/Cas9 library screening for drug target discovery." J Hum Genet. 2017 Nov 20. Epub ahead of print.
Carlson M, Watson AL, Anderson L, Largaespada DA, Provenzano PP. "Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors." J Biomed Opt. 2017 Nov; 22(11): 1-9.
October 25, 2017: Dr. Largaespada was renewed as an American Cancer Society Research Professor and will be highlighted in the October edition of the Institute for Engineering in Medicine Newsletter.
Scott MC, Temiz NA, Sarver AE, LaRue RS, Rathe SK, Varshney J, Wolf NK, Moriarity BS, O'Brien TD, Spector LG, Largaespada DA, Modiano JF, Subramanian S, Sarver AL. "Comparative transcriptome analysis quantifies immune cell transcript levels, metastatic progression and survival in osteosarcoma." Cancer Res. 2017 Oct 24. Epub ahead of print.
October 14, 2017: Dr. Largaespada joined several members from the University of Minnesota Brain Tumor Program at the ABTA's BT5K around Lake Como. View information on our team website.
Tschida BR, Temiz NA, Kuka TP, Lee LA, Riordan JD, Tierrablanca CA, Hullsiek R, Wagner S, Hudson WA, Linden MA, Amin K, Beckmann PJ, Heuer RA, Sarver AL, Yang JD, Roberts LR, Nadeau JH, Dupuy AJ, Largaespada DA. "Sleeping Beauty insertional mutagenesis in mice identifies drivers of steatosis-associated hepatic tumor." Cancer Res. 2017 Oct 9. Epub ahead of print.
October 2-4, 2017: Dr. Largaespada attended the Annual Synodos Meeting in Palm Beach, Florida.
Riordan JD, Feddersen CR, Tschida BR, Jackson P, Keng VW, Linden MA, Amin K, Stipp CS, Largaespada DA, Dupuy AJ. "Chronic liver injury alters driver mutation profiles in hepatocellular carcinoma." Hepatology, 2017 Sep 29. Epub ahead of print
September 28, 2017: Dr. Largaespada presented “Transposon-Based Mouse Models for Finding Drivers of Specific Cancer Behaviors” as part of the Development & the Pathogenesis of Disease Series at the University of Kansas Medical Center, Kansas City, KS.
September 24-27, 2017: Dr. Largaespada presented a talk at Advances in Modeling Cancer in Mice: Technology, Biology and Beyond which is an AACR Special Conference in Orlando, Florida.
September 21-23, 2017: Dr Largaespada along with Kyle Williams, Mark Sokolowski, Sara Isakson, Bryant Keller, and German Velez Reyes attended the Sarcoma in Neurofibromatosis Retreat at the Marine Biology Laboratory in Woods Hole, MA along with several collaborators in the Nancy Ratner lab from the Cincinnati Children's Hospital.
Kawakami K, Largaespada DA, Ivics Z. "Transposons as tools for functional genomics in vertebrate models." Trends Genet. 2017 Sep 6. Epub ahead of print.
Kyle Williams, PhD, postdoctoral fellow in David Largaespada's laboratory and past Cancer Biology Training Grant member, was named a Children's Tumor Foundation Young Investigator and awarded a two-year fellowship for the study of nervous system tumors associated with Neurofibromatosis Type 1.
August 11-13, 2017: The Largaespada lab participated in Chainbreaker: A Movement to End Cancer. They created a Peloton (team) called The Little Ras-Cals, which had 16 riders and raised $10,739. All funds were donated to cancer research at the Masonic Cancer Center, University of Minnesota. Members of the team included: David Largaespada, R. Scott McIvor, Zohar Sacks, Kyle Williams, Robin Williams, Flavia Popescu, Germán Vélez Reyes, Sara Isakson, Emily Pomeroy, Nicholas Slipek, Alex Larsson, Jason Ostergaard, Samual Finnerty, Kyle Meek, Kevin Osum, and Steve Sanderson. View their peloton at The Little Rascals page.
August 7, 2017: Dr. Largaespada was invited to give a seminar titled "Tracking Down Cancer Using Transposon Mutagenesis and Targeted Nucleases” at Genentech, San Francisco, CA.
July 29, 2017: The lab enjoyed the 10th Annual Largaespada Lake Party at Lake Washington.
July 18-20, 2017: Dr. Largaespada was an invited speaker at the 5th Annual Tumor Models Boston Summit, Boston, MA, "Pre-clinical mouse models of cancer via transposon-mediated mutagenesis or gene transfer."
Dr. Largaespada received a grant from The Sarcoma Foundation of Americaon mechanisms of osteosarcoma chemotherapy resistance titled "Identifying Chemoresistance Pathways in Osteosarcoma".
Dr. Largaespada received a 2017 CCRF Research Grant Award on osteosarcoma titled "Molecular and cellular determinants of metastatic osteosarcoma chemoresistance
Kyle Williams PhD received the Children's Tumor Foundation Young Investigator Award and Fellowship. This is a two year appointment, working to identify novel therapeutic targets and develop treatments for use against NF1-associated tumors and malignancies.
June 23, 2017: Dr. Largaespada was invited to give a special seminar titled "Transposon-Based Mouse Models for Finding Drivers of Specific Cancer Behaviors" at The Hong Kong Polytechnic University, Department of Applied Biology and Chemical Technology, Kowloon, Hong Kong.
June 19-22, 2017: Dr. Largaespada was an invited speaker at the 4th Macau Symposium on Biomedical Sciences. “Transposon-Based Mouse Models for Finding Drivers of Specific Cancer Behaviors.” Macau, China.
June 10-13 2017: Dr. Largaespada served on the review committee to score the basic science abstracts at the 2017 Children's Tumor Foundation Neurofibromatosis Conference, in Washington D.C.
Oral Presentations from members at Children's Tumor Foundation Neurofibromatosis Conference:
- Exploiting novel vulnerabilities in NF1-associated tumorigenesis: A small molecule screen identifies compounds capable of selectively killing NF1 deficient human Schwann cells.
- Kyle B Williams PhD1, Rory L Williams BS1, Sam A Finnerty BS1, Adrienne L Watson PhD2, Sue Rathe PhD1, Jon Hawkinson PhD1, Gunda Georg PhD1, Christopher L Moertel MD1, David A Largaespada PhD1, 1University of Minnesota, 2Recombinetics Inc.
- A Swine Model of Neurofibromatosis Type I
- Adrienne L Watson PhD2, Sara Isakson DVM1, Alex Coutts BS2, Kyle Williams PhD1, Rory Williams BS1, Daniel F Carlson PhD2, Christopher L Moertel MD1, Scott C Fahrenkrug2, David A Largaespada PhD1, 1University of Minnesota, 2Recombinetics Inc.
Poster Presentations from members at Children's Tumor Foundation Neurofibromatosis Conference:
- Perturbation of the Hyaluronan-Rich Nerve Sheath Tumor Microenvironment to Improve Drug Efficacy and Delivery
- Bryant J Keller BS1, Adrienne Watson PhD2, Kyle Williams PhD1, Rory Williams BS1, Leah Anderson BS1, Marjorie Carlson BS1, Justin Knight BS1, Colleen Forster BS3, Kwangmin Choi BS4, Nancy Ratner PhD4, Co-Senior: Paolo Provenzano PhD1, Co-Senior: David Largaespada PhD1. Affiliations: 1University of Minnesota, 2Recombinetics Inc., 3BioNet, 4Cincinnati Children's Hospital
June 17, 2017: Several members of lab joined the University of Minnesota Brain Tumor Program attended the Annual Step Up for NF Fundraiser Walk hosted by NF Upper Midwest at Lake Como.
Pomeroy EJ, Lee LA< Lee RDW, Schirm DK, Temiz NA, Ma J, Gruber TA, Diaz-Flores E, Moriarity BS, Downing JR, Shannon KM, Largaespada DA, Eckfeldt CE. "Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia." Oncogene. 2017 Jun 8; 36(23): 3263-3273.
David Largaespada PhD, Kyle Williams PhD, and Germán Vélez Reyes traveled to Cincinnati to meet with our long-term collaborator Dr. Nancy Ratner and the members of her team.
Paul JA, Aich A, Abrahante JE, Wang Y, LaRue RS, Rathe SK, Kalland K, Mittal A, Jha R, Peng F, Largaespada DA, Bagchi A, Gupta K. "Transcriptomic analysis of gene signatures associated with sickle pain." Sci Data. 2017 May 16; 4:170051.
The University of Minnesota group of researchers that are one of three consotia for the Children's Tumor Foundation Synodos for NF1 were highlighted in a video on the CTF website.
Sachs Z, Been RA, DeCoursin KJ, Nguyen HT, Mohd Hassan NA, Noble-Orcutt KE, Eckfeldt CE, Pomeroy EJ, Diaz-Flores E, Geurts JL, Diers MD, Hasz DE, Morgan KJ, MacMillan ML, Shannon KM, Largaespada DA, Wiesner SM. "Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency." Haematologica. 2016 Oct; 101(10): 1190-1199.
Morrissy AS, Largaespada DA, et al. "Divergent clonal selection dominates medulloblastoma at recurrence." Nature. 2016 Jan 21; 529(7586): 351-357.